Next Article in Journal
Sexual Dysfunction and Quality of Life in Chronic Heroin-Dependent Individuals on Methadone Maintenance Treatment
Previous Article in Journal
Association of Glucose Fluctuations with Sarcopenia in Older Adults with Type 2 Diabetes Mellitus
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
JCM
Volume 8
Issue 3
10.3390/jcm8030320
jcm-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis

by
Marzia Dolcino
1,
Elisa Tinazzi
1,
Antonio Puccetti
2,† and
Claudio Lunardi
1,*,†
1
Department of Medicine, University of Verona, 37134 Verona, Italy
2
Department of Experimental Medicine, Section of Histology, University of Genova, 16132 Genova, Italy
*
Author to whom correspondence should be addressed.
†
These authors contributed equally to this work.
J. Clin. Med. 2019, 8(3), 320; https://doi.org/10.3390/jcm8030320
Submission received: 28 January 2019 / Revised: 25 February 2019 / Accepted: 4 March 2019 / Published: 7 March 2019
(This article belongs to the Section Immunology)
Browse Figures
Versions Notes

Abstract

:
Systemic sclerosis (SSc) is an autoimmune disease characterized by three main features: vasculopathy, immune system dysregulation and fibrosis. Long non-coding RNAs (lncRNAs) may play a role in the pathogenesis of autoimmune diseases and a comprehensive analysis of lncRNAs expression in SSc is still lacking. We profiled 542,500 transcripts in peripheral blood mononuclear cells (PBMCs) from 20 SSc patients and 20 healthy donors using Clariom D arrays, confirming the results by Reverse Transcription Polymerase-chain reaction (RT-PCR). A total of 837 coding-genes were modulated in SSc patients, whereas only one lncRNA, heterogeneous nuclear ribonucleoprotein U processed transcript (ncRNA00201), was significantly downregulated. This transcript regulates tumor proliferation and its gene target hnRNPC (Heterogeneous nuclear ribonucleoproteins C) encodes for a SSc-associated auto-antigen. NcRNA00201 targeted micro RNAs (miRNAs) regulating the most highly connected genes in the Protein-Protein interaction (PPI) network of the SSc transcriptome. A total of 26 of these miRNAs targeted genes involved in pathways connected to the three main features of SSc and to cancer development including Epidermal growth factor (EGF) receptor, ErbB1 downstream, Sphingosine 1 phosphate receptor 1 (S1P1), Activin receptor-like kinase 1 (ALK1), Endothelins, Ras homolog family member A (RhoA), Class I Phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), p38 mitogen-activated protein kinase (MAPK), Ras-related C3 botulinum toxin substrate 1 (RAC1), Transforming growth factor (TGF)-beta receptor, Myeloid differentiation primary response 88 (MyD88) and Toll-like receptors (TLRs) pathways. In SSc, the identification of a unique deregulated lncRNA that regulates genes involved in the three main features of the disease and in tumor-associated pathways, provides insight in disease pathogenesis and opens avenues for the design of novel therapeutic strategies.

1. Introduction

Systemic Sclerosis (SSc) is a rare autoimmune disease characterized by endothelial disfunction, dysregulation of the immune system and increased extracellular matrix deposition leading to extended involvement and fibrosis of skin and internal organs and resulting in a remarkable heterogeneity in clinical features and in disease course [1].
Several factors have been shown to contribute to the onset of the disease, such as genetic susceptibility, environmental factors including viral infections [2,3] and epigenetic mechanisms, such as microRNAs (miRNAs) [4,5].
We have already reported the gene expression profiling of peripheral blood mononuclear cells (PBMCs) obtained from patients affected by SSc [6] showing the presence of cancer-related gene signatures.
Indeed, an increased frequency of different types of cancer, including breast, lung, and hematologic malignancies in SSc has been already described [7], and has been associated with the presence of particular autoantibodies [8]. In addition, SSc may also be a paraneoplastic disease [9,10] suggesting a strong link with cancer.
In this study we focused our attention on the epigenetic mechanisms that may be involved in SSc pathogenesis by analyzing the expression profiles of long non-coding RNAs (lncRNAs) in SSc patients.
For the first time, we propose an integrated analysis of lncRNAs, miRNAs and gene expression profiles in SSc patients leading to the identification of lncRNAs modulated in the disease. We identified a lncRNA involved both in pathogenetically relevant molecular pathways of the disease and in tumor-associated pathways, strongly associated to the disease.

2. Materials and Methods

2.1. Patients

Twenty patients affected by SSc, attending the Unit of Autoimmune Diseases at the University Hospital of Verona, Northern Italy, and 20 sex and age matched healthy controls were enrolled. Both patients and controls were subjects of Caucasian origin from Northern Italy. All patients were diagnosed accordingly to the American College of Rheumatology (ACR)/European League Against Rheumatism (Eular) classification criteria for SSc [11]. The distinction between limited (lSSc) and diffuse cutaneous SSc (dSSc) was performed following the criteria proposed by Le Roy et al. [12]. Ten patients were affected by lSSc and 10 by dSSc. The clinical and demographic features of the patients enrolled in the study are reported in Table 1.
Samples obtained from 10 patients with lSSc, 10 patients with dSSc and 20 healthy controls were used for the gene and lncRNAs expression analysis. Blood samples were collected from patients with active disease (European Scleroderma Study Group activity index > 3) [13] within 24 months after diagnosis and in the absence of immunosuppressive therapies. Samples were processed immediately after the blood draw.
Twenty more patients and 20 healthy controls have been analyzed as validation groups (Supplementary Table S1).
A written informed consent was obtained by all the participants to the study and the study protocol was approved by the Ethical Committee of the Azienda Ospedaliera Universitaria Integrata di Verona. All the investigations have been performed according to the principles contained in the Helsinki declaration.

2.2. Microarray Analysis

Blood samples collection was performed using BD (Becton Dickinson)Vacutainer K2EDTA tubes and 21-gauge needles.
PBMCs were isolated by Ficoll–HyPaque (Pharmacia Biotech, Quebec, Canada) gradient centrifugation. The PBMCs distribution was similar between patients and controls. Total RNA extraction from PBMCs (107 cells) was achieved with miRNeasy mini kit (Qiagen GmbH, Hilden, Germany). cRNA preparation, samples hybridization and scanning were carried out following the Affymetrix (Affymetrix, Santa Clara, CA, USA) provided protocols, by Cogentech Affymetrix microarray unit (Campus IFOM IEO, Milan, Italy). All samples were hybridized on Human Clariom D (Thermo Fisher Scientific, Waltham, MA, USA) gene chip. Signal intensities were analyzed with the Transcriptome Analysis Console (TAC) 4.0 software (Applied Biosystem, Foster City, CA USA by Thermo Fisher Scientific).
The Human Clariom D arrays interrogates more than 540,000 human transcripts starting from as little as 100 pg of total RNA. Signals intensity was background-adjusted, normalized, and log-transformed using the Signal Space Transformation (SST)-Robust Multi-Array Average algorithm (RMA).
Differentially expressed genes that showed an expression level at least 1.5 fold different in the test sample versus control sample at a significant level (p ≤ 0.01) were chosen for final consideration. p-values were calculated applying the unpaired t-test and Bonferroni multiple testing correction.
Targets annotations of ncRNA00201 were retrieved using starBase v2.0 (http://starbase.sysu.edu.cn/) where lncRNAs interactions, experimentally validated by high-throughput experimental technologies, are registered [14].
The list of Gene targets of microRNAs (miRNAs) that are targeted by ncRNA00201 were obtained from the FunRich database (www.funrich.org/) [15].

2.3. Protein–Protein Interaction (PPI) Network Construction and Network Clustering

The PPI network was constructed upon the experimentally validated protein–protein interactions using STRING (Search Tool for the Retrieval of Interacting Genes) version 10.5 (http://string-db.org/) [16].
Network topological analysis was performed using the Cytoscape software (version 3.4.0) (www.cytoscape.org) [17].
High-flow areas (highly connected regions) of the network (modules) were detected using the MCODE plugin of Cytoscape (k-core = 4 and node score cutoff = 0.2).

2.4. Gene Functional Classification and Enrichment Analysis

Functional classification of genes into Biological Processes (BPs) were performed according to the Gene Ontology (GO) annotations (www.geneontology.org) using Panther expression analysis tools (version 14.0) (http://pantherdb.org/) [18].
Pathways classification and enrichment (hypergeometric p-value ≤0.05) analysis were performed with FunRich (version).

2.5. Real Time PCR of ncRNA00201

A total of 500 ng of total RNA was treated with 1 unit of DNase I Amplification Grade (Invitrogen; Carlsbad, CA, USA.). First-strand cDNA was generated using the SuperScript IV First-Strand Synthesis System (Invitrogen; Carlsbad, CA, USA.) with random hexamers, according to the manufacturer’s protocol. Real time PCR was performed in triplicate with PowerUp™ Sybr® Green reagent (Applied Biosystems; Foster City, CA, USA) in a QuantStudio 6 Flex system (Applied Biosystems; Foster City, CA, USA). Relative expression levels were calculated for each sample after normalization against the geometric mean of the housekeeping genes GAPDH and beta-actin (ACTB) expression. The ΔΔCt method was used for comparing relative fold expression differences. The data are expressed as fold changes with respect to healthy. The primers used for the detection were: GCA GGA GAA TCG CTT GAA C (forward) and ACC CTA CCA TCC AAC TTC AC (reverse).

2.6. Real Time PCR of Genes Modulated in SSc Patients

First-strand cDNA was generated using the SuperScript III First-Strand Synthesis System for Reverse transcription Polymerase-chain Reaction (RT-PCR) Kit (Invitrogen), with random hexamers, according to the manufacturer’s protocol. PCR was performed in a total volume of 25 μL containing 1× Taqman Universal PCR Master Mix, no AmpErase UNG and 2.5 μL of cDNA; pre-designed, Gene-specific primers and probe sets for each gene were obtained from Assay-on-Demande Gene Expression Products (Applied Biosystems).
Real Time PCR reactions were carried out in a two-tube system and in singleplex. The Real Time amplifications included 10 min at 95 °C (AmpliTaq Gold activation), followed by 40 cycles at 95 °C for 15 s and at 60 °C for one minute. Thermocycling and signal detection were performed with 7500 Sequence Detector (Applied Biosystems). Signals were detected according to the manufacturer’s instructions. This technique allows the identification of the cycling point where PCR product is detectable by means of fluorescence emission (Threshold cycle or Ct value). The Ct value correlates to the quantity of target mRNA. Relative expression levels were calculated for each sample after normalization against the housekeeping genes GAPDH, beta-actin and 18s ribosomal RNA (rRNA), using the ΔΔCt method for comparing relative fold expression differences. Ct values for each reaction were determined using TaqMan Software and Digital Store (SDS) analysis software (version 2.4.0). For each amount of RNA tested triplicate Ct values were averaged. Because Ct values vary linearly with the logarithm of the amount of RNA, this average represents a geometric mean.

2.7. Real Time PCR of microRNAs Targeted by ncRNA00201

miRNAs expression was assayed by TaqMan® Advanced miRNA assays chemistry (Applied Biosystems, Foster City, CA, USA). Briefly, 10 ng of total RNA was reverse transcribed and pre-amplified with TaqMan® Advanced miRNA cDNA synthesis kit following manufacturer’s instructions (Applied Biosystems, Foster City, CA, USA). Pre-amplified cDNA was diluted 1/10 in nuclease-free water and 5 µL of diluted cDNA for each replicate were loaded in PCR. 20 µL PCR reactions were composed by 2X Fast Advanced Master Mix and TaqMan® Advanced miRNA assays for miR-30b-5p, miR-30e-5p, miR-302a-3p, miR-520d-3p, miR-613 and miR-9-5p. The mean of Ct for hsa-miR-16-5p and hsa-miR-26a-5p expression was used to normalize miRNA expression. Real time PCR were carried out in triplicate on a QuantStudio 6 Flex instrument (Applied Biosystems, Foster City, CA, USA). Expression values were reported as fold change with respect to healthy controls by ΔΔCt method using QuantStudio Real-Time PCR system software v. 1.3.

2.8. Detection of Soluble Mediators in Sera of SSc Patients

Serum levels of interleukin-6 (IL-6), macrophage migration inhibitory factor (MIF) selectin P (SELP) chemokine C-X-C motif ligand 10, (CXCL10) and basigin (BSG) were detected using commercially available Enzyme-Linked Immunosorbent Assay (ELISA) kits that were supplied by Aviva Systems Biology (IL-6; cat. n. OKDB00046), R&D (MIF; cat n. DMF00B and SELP; cat. n. DPSE00), Life Span Biosciences (LSBio) (CXCL10; cat. n. LS-F586-1) and Creative Diagnostics (BSG; cat n. DEIA2873).

3. Results

With the aim of identifying lncRNAs potentially involved in SSc pathogenesis, the expression of more than 540,000 human transcripts, including those ascribed to more than 50,000 lncRNAs was profiled at the same time, in a cohort of 40 PBMCs samples (20 SSc and 20 healthy subjects). Transcriptional profiles of SSc patients and healthy subjects were compared and, after a robust filtering procedure (Bonferroni-corrected p-value ≤ 0.01 and fold change ≥ |1.5|), 837 coding-genes were significantly modulated (Supplementary Table S2). More than one hundred lncRNAs were detectable, but only one, long non-coding heterogeneous nuclear ribonucleoprotein U antisense RNA 1 (HNRNPU-AS1, also known as ncRNA00201) satisfied the above mentioned criteria (statistical and fold change) showing a significant modulation (Table 2).
ncRNA00201 has been showed to be overexpressed in pancreatic ductal adenocarcinoma (PDAC) tissues and cell lines, and plays a role in the regulation of cell proliferation, invasion, and migration. Indeed, the knockdown of this lncRNA reduces proliferation and in vitro migration and invasion of PDAC cell lines [19].
The functional classification by Gene Ontology (http://www.geneontology.org/) of the 837 differentially expressed genes (DEGs) revealed the presence of a large number of differentially expressed coding genes involved in biological processes (BPs) and signaling pathways that are strictly connected to SSc pathogenesis, including, immune response BP, interferon alpha/beta signaling, IL-6 mediated signaling events BP, inflammatory response BP, apoptosis BP, angiogenesis BP, Vascular Endothelial Growth Factor (VEGF) and VEGFR signaling, cell adhesion BP, blood coagulation BP, endothelin signaling, PDGFR-beta signaling, EGF receptor (ErbB1) signaling, TGF-beta receptor signaling, extracellular matrix (ECM) component and organization, proteoglycan syndecan mediated signaling events, and positive regulation of fibroblast proliferation BP.
Table 2 shows a selection of DEGs involved in these meaningful biological processes and pathways.
The modulation of genes involved in immune response highlighted the immune system alterations that characterize SSc and other autoimmune diseases. Not surprising, in SSc samples we found upregulation of genes belonging to the type alpha and beta interferon signaling pathways, that is a common trait of autoimmune diseases and, this finding has also been previously overserved in SSc PBMCs [20]. In addition, we found a strong upregulation of interleukin-6 (IL-6) (F.C. 12.69) a cytokine involved in inflammatory and autoimmune diseases including SSc and, besides that, we found overexpression of several members of its signaling pathway (see Table 2).
The presence of modulated genes involved in the inflammatory process reflected the chronic inflammation that accompanies SSc. Moreover the upregulation of genes involved in apoptosis is not surprising, since apoptosis is the first event of vascular damage in early SSc [2]. The modulation of genes involved in angiogenesis gives evidence of the angiogenic response to tissue ischemia and vascular damage that occurs in the initial stages of SSc. We also have to mention that, members of the proangiogenetic VEGF and VEGFR signaling pathway were modulated in SSc (see Table 2).
The vascular response to endothelial damage consists of endothelial activation with increased expression of adhesion molecules and, indeed, several adhesion molecules were overexpressed in SSc samples.
As it is well known, the spectrum of vascular abnormalities that characterizes SSc also involves disorders of the blood coagulation-fibrinolysis system [21] and, noteworthy, we found upregulation of several genes involved in blood coagulation.
The earliest vascular changes in SSc also include a dysregulated control of vascular tone and indeed we have to mention that endothelins are among the strongest vasoconstrictors known, and are involved in vascular diseases of several organs. Interestingly in SSc samples several components of the endothelins pathway were overexpressed.
Moreover, we found modulation of members of the platelet derived growth factor receptor-beta (PDGFR-B). PDGFR-B has been implicated in SSc [22] and it plays a role in activation of the epidermal growth factor receptor (EGFR) that is also involved in the disease. In particular, in scleroderma fibroblasts, aberrant activation of EGF-mediated signaling pathways, can upregulate the receptor II of transforming growth factor beta (TGFBRII) [23], the growth factor primary playing a role in the development of connective tissue fibrosis that is typically involved in SSc pathogenesis and, noteworthy, members of the EGFR pathway were modulated in SSc. Moreover the deregulation of both PDGF and EGF pathways has been already described in a previous study on gene expression profiles in SSc peripheral blood [24].
Consistently with these findings, other modulated genes were involved in the signaling of the profibrotic cytokine TGF-beta.
Fibrosis is supported by extracellular matrix (ECM) remodeling and, consistently, we found overexpression of ECM components and of molecules involved in ECM organization. Moreover, we found an increased expression of molecules involved in proteoglycan syndecan-mediated signaling events (see Table 2) and of genes involved in the positive regulation of fibroblasts proliferation.
The expression levels of ncRNA00201, selected miRNAs and coding genes were validated by RT-PCR in the entire series of the analyzed patients and in an expanded panel of SSc patients (20) and healthy controls (20 subjects) (Supplementary Table S1). Significantly different expression levels were found for all tested transcripts as compared to healthy controls (Supplementary Figures S1 and S2).
Gene expression results were also confirmed by the detection of several soluble mediators (including interleukin-6, IL-6; macrophage migration inhibitory factor, MIF; selectin P, SELP; chemokine C-X-C motif ligand 10, CXCL10 and basigin, BSG) in the sera of SSc patients. As shown in Supplementary Figure S3 the serum levels of all the tested molecules were significantly different in SSc patients when compared to healthy donors.
Noteworthy, the pathways enrichment analysis confirmed that the important signaling networks described in Table 2 were all included in the list of pathways significantly (p < 0.05) enriched in the 837 genes, along with others that were likewise connected to autoimmune and inflammatory response, vascular damage (i.e., apoptosis, platelet activation and aggregation, Urokinase-type plasminogen activator (uPA) and uPAR-mediated, Thrombin/protease-activated receptor (PAR) signaling etc.) and fibrosis (i.e., glypican, syndecan-3 mediated, regulation of nuclear Small Mother Against Decapentaplegic (SMAD) 2/3 signaling etc.) (Supplementary Table S3).
Since modulated genes were well representative of the main features of the disease, we decided to verify if the only modulated lncRNA could be functionally connected to SSc transcriptome, thus playing a role in SSc pathogenesis. To this purpose we extracted the complete list of experimentally validated genes and microRNAs (miRNAs) targets of ncRNA00201, and we found that 56 miRNAs and 31 genes were annotated as target of ncRNA00201 (Supplementary Table S4). One of the gene targets, named hnRNPC, belonged to a subfamily of ubiquitously expressed heterogeneous nuclear ribonucleoproteins (hnRNPs) and interestingly encoded for a known antigen identified in SSc [25].
To dissect all the possible connections between ncRNA00201 and the SSc transcriptome we analyzed the lists of genes targeted by each of the 56 miRNAs (3759 genes) selecting only transcripts that also resulted significantly modulated on the array. Among the 3759 gene targets, 138 were modulated in SSc patients and were further analyzed along with their targeting miRNAs (47/56) (Supplementary Table S5). We therefore selected only those miRNAs that targeted genes with evidence of modulation in SSc patients to bona fide outline authentic interactions that are most probably established in SSc.
The analysis of signaling pathways, in which the 138 DEGs may be involved, showed that these genes were present in the 83% (147/176) of pathways significantly enriched in the SSc transcriptome (Supplementary Table S6).
A protein–protein interaction (PPI) network including all the protein products of the 837 modulated genes that showed experimentally validated interactions was constructed and, the obtained network included 693 nodes (interacting partners) and 2226 edges (interactions), showing a good PPI enrichment p-value (<10−16) indicating that the network contained significantly more interactions than expected. In other words, the connected proteins had more interactions among themselves than what would be expected for a random set of proteins of similar size, drawn from the genome. Such an enrichment indicates that these proteins are biologically connected, as a group.
The topological analysis of the PPI network showed the presence of a large number of targeted genes in areas with high density of connections (Figure 1).
When a modular analysis was performed, we could identify six areas of the PPI network in which the most highly connected genes were present (modules).
Since the modulation of highly connected genes is expected to have a wider impact on the transcriptome than the targeting of several isolated genes, we checked if ncRNA00201 could target genes included in the modules and, noteworthy, we observed that genes modulated by miRNA targets of ncRNA00201 were present in each of the 6 modules (Supplementary Table S7).
To dissect the most relevant interactions through which ncRNA00201 could influence the pathogenesis of the disease, the miRNAs targeted by ncRNA00201 were filtered, prioritizing those that targeted at least 7 genes in the whole SSc transcriptome (i.e., the 837 modulated genes) and at least two modules. By these criteria, 26 miRNAs target of ncRNA00201 were selected. Table 3 shows the 26 selected miRNAs and summarizes their targeted genes in the SSc transcriptome and in the modules.
Interestingly, among the selected miRNAs, miR-30b-5p and miR-31-5p were previously described as deregulated in SSc whereas, all the 26 miRNAs are modulated in several types of human cancer (Table 3).
The selected miRNAs targeted module-associated-genes with important biological significance, indeed these genes were involved in inflammation, in the modulation of immune response regulating signaling, in maintaining vascular homeostasis, in tissue remodeling, and also in metastasis development in many cancers.
Indeed, Module 1 (M1) was targeted by 20 miRNAs (see Table 3) that globally modulated SOCS3, UBE2F, UBE2J1, IRF9, and CBLB. SOCS3, a major regulator of inflammation, is rapidly induced by JAK-STAT (Janus kinase-signal transducer and activator of transcription) signaling during the inflammatory response. UBE2F and UBE2J1 are ubiquitin conjugating enzymes that are involved in inflammation and in metastasis development in many cancers [54]. IRF9 is strongly induced by type I interferons and CBLB is involved in the regulation of immune response modulating signaling by both T-cell and B-cell receptors [55].
M2 was targeted by eight miRNAs including the members of the miRNA 30s family (miR-30a, 30b, 30c, 30d, and 30d-5p miRNAs) that targeted GNAI2 and miR-206, miR-9-5p and miR-613 that modulated CXCL11. GNAI2 plays a role in chemokine receptor signaling in B-cells [56] and CXCL11 is a proinflammatory molecule whose serum levels are increased in SSc [57].
M3 was targeted by miR-31-5p that modulated KDELR2. This molecule is involved in extracellular matrix degradation and in the signaling of the Src family proteins that is activated during cell invasion leading to metastasis development [58].
In M4 the gene APIS3 was targeted by members of the miR-181s family (including miR-181-a/b/c/d-5p). Lacking of AP1S3 gene has been associated to the development of skin inflammation [59] and interestingly, AP1S3 was down-modulated in SSc samples (see Supplementary Table S1).
M5 was the most targeted module since it was targeted by 21 out of the 26 selected miRNAs (see Table 3). In this module 5 genes were targeted including GCH1, GUCY1A3, PAX5, SPARC and BCL2. GCH1, also named GTPCH1 is implicated in the synthesis of the three nitric oxide synthases (NOS1–3) [60] and endothelial cell GCH1-dependent endothelial nitric oxide (eNOS) regulation plays an important role in maintaining vascular homeostasis [61]. GUCY1A3 encodes for the α1 subunit of nitric oxide (NO) receptor and is involved in the control of smooth muscle cells relaxation [62].
PAX5 is indispensable for the B-cell lineage specification and maintenance [63] and has been implicated in human B cell malignancies, including acute lymphoblastic leukemias and non-Hodgkin lymphomas [64].
SPARC (also known as osteonectin) is a glycoprotein of the extracellular matrix expressed in concomitance with tissue remodeling and wound repair. Interestingly SPARC upregulation has been described in cultured dermal fibroblasts from patients with SSc [65] and it has been observed that SPARC silencing can reduce collagens overproduction in SSc skin fibroblasts [66].
The BCL2 gene is involved in apoptosis and its co-expression with the oncogene MYC is associated with a poor prognosis in B-cell lymphoma patients [67]. Interestingly both BCL2 and MYC were upregulated in SSc patients (see Supplementary Table S1).
In module M6, PSME1 was targeted by miR-204-5p and miR-211-5p. PSME1, also named PA28, is a proteasome component that influences antigen processing. Proteasomal system plays crucial roles in important biological processes including cell differentiation, proliferation, apoptosis, transcriptional activation and angiogenesis, and is a pivotal target for treatment of several diseases including autoimmune diseases and cancer [68].
We also observed that a large proportion of the pathways enriched (p < 0.05) in modulated genes targeted by the 26 selected miRNAs were linked to the three main features of the disease (i.e., immune and inflammatory response, vasculitis and fibrosis) thus confirming their possible involvement in SSc pathogenesis. Figure 2 shows a selection of the above mentioned enriched signaling pathways in which are involved modulated genes targeted by 11 of the 26 selected miRNAs.
Interestingly, several of the aforementioned pathways are also deregulated in many forms of cancer. These pathways included for example EGF receptor, ErbB1 downstream, Sphingosine-1-phosphate receptor 1 (S1P1), Arf6 downstream, ALK1, Endothelins, RhoA, Class I PI3K (Phosphatidylinositol 3-kinase), mTOR, p38 MAPK, RAC1, TGF-beta receptor, MyD88 and Toll-like receptors signaling pathways (Figure 3).
We thereafter aimed at identifying modulated genes targeted by the selected miRNAs whose deregulation could have the widest impact on the global disease-associated gene modulation. We therefore narrowed our analysis to modulated genes targeted by the 26 miRNAs that were included in the six modules and we identified five transcripts, namely IRF9, GUCY1A3, SOCS3, BCL2 and GNAI2 that were targeted by the highest number of selected miRNAs (see Table 2).
Interestingly, we observed that they were associated to a large number of pathways (136) and that 82 (60%) of such pathways are significantly enriched (p < 0.05) in the whole SSc transcriptome such as for example interferon alpha/beta, apoptosis, endothelins, PDGF receptor beta, TGF-beta receptor and regulation of SMAD (Supplementary Table S8).

4. Discussion

Though it has been widely recognized that lncRNAs play a pivotal role in the regulation of autoimmune diseases [69], an extensive analysis of lncRNAs in SSc is still lacking. We therefore performed a comprehensive analysis assessing the expression profiles of a very large number of lncRNAs in SSc patients, and we could find that, differently from what we had already observed in other autoimmune diseases [70], a single lncRNA, namely ncRNA00201, appeared to be significantly modulated in SSc.
Among the gene targets of ncRNA00201, there is the hnRNPC, which encodes for a known autoantigen in SSc [25].
Interestingly, ncRNA00201 has been showed to be involved in cancer proliferation [19] and this finding may reinforce the hypothesis of a link between SSc and tumor development, as we have recently suggested [6].
By a combined analysis of the expression profiles of a vast number of coding and non-coding transcripts, we have been able to observe that ncRNA00201 alone controls biological processes and pathways closely related to the three main features of SSc, including immune and inflammatory response, vasculitis and fibrosis.
We moreover identified 26 miRNAs by which ncRNA00201 could modulate the expression of several genes crucial to the disease, thus highlighting the most effective lncRNA-miRNA-gene interactions in SSc. Interestingly, all the 26 miRNAs are modulated in several types of human cancer.
We also showed that ncRNA00201 is able to modulate pathways that are associated to both SSc and tumor development such as EGF receptor, ErbB1 downstream, S1P1, Arf6 downstream, ALK1, Endothelins, RhoA, Class I PI3K, mTOR, p38 MAPK, RAC1, TGF-beta receptor, MyD88 and Toll-like receptors signaling pathways, confirming our previous observations [6].
Indeed, changes in EGFR expression and autoantibodies to this receptor have been observed in patients with SSc [71], nevertheless there is evidence for the involvement of EGFR signaling in the development of different carcinoma types [72].
The activation of S1P signaling pathway can induce many of the alterations observed in SSc patients [73], moreover, S1P receptors regulate cell proliferation in various tumors [74].
Arf6 is involved in angiogenesis [75] and is implicated in tumor metastasis [76]. ALK1 inhibition reduces pro-fibrotic genes expression in SSc fibroblasts [77] moreover, this gene is an emerging target for antiangiogenic therapy in cancer [78]. Endothelins (ET) play important roles in the in the fibrotic process associated to SSc and have a documented role in the development of cancer [79]. RhoA signaling, is frequently altered in many types of human tumors [80] and the expression of RhoA is elevated in SSc endothelial cells [81].
PI3K signaling is involved in collagen gene expression and in the antiapoptotic phenotype that characterizes SSc fibroblasts [82,83]. This pathway acts in synergy with the mTOR signaling in the development of many cancers [84]. Interestingly, mTOR blockade can reduce the pro-fibrotic action of TGF-beta and its therapeutic implications for SSc have been suggested [85].
The p38 MAPK and the Rac1 signaling were also associated to SSc fibrosis [86,87] and to cancer progression [88,89].
Finally, other signaling typically involved in both SSc and cancer development are TGF-beta receptor and MyD88/Toll-like receptors pathways [90,91,92,93].
In conclusion, this study is the first report of a unique lncRNA that controls gene networks that may contribute to SSc pathogenesis and that may play a predisposing role to the well documented development of malignancies in SSc.
Finally, we may propose that ncRNA00201 may be a potential target in the development of novel therapeutic strategies.

Supplementary Materials

The following are available online at https://www.mdpi.com/2077-0383/8/3/320/s1, Table S1. Demographic and Clinical features of SSc patients and healthy controls that were enrolled as validation cohort. Table S2. Genes modulated in SSc patients versus healthy subjects. Table S3. Signaling pathways significantly enriched (p < 0.05) in genes modulated in SSc patients. Table S4. MicroRNAs and genes that are annotated as targets of ncRNA00201 in StarBase. Table S5. Modulated genes in SSc that are regulated by miRNA targets of ncRNA00201. Table S6. Pathways in which are involved the 138 modulated genes that are targeted by miRNAs modulated by ncRNA00201. Pathways significantly enriched in the 837 genes that were modulated in SSc patients are highlighted in orange. Table S7. Modulated genes in SSc that are included in modules. Genes targeted in the six modules are written in bold characters. Table S8. Signaling pathways in which are involved the five selected genes modulated in SSc. Figure S1. Expression of ncRNA00201 and of selected miRNAs targeted by ncRNA00201 in the 20 SSc patients and healthy controls analyzed in the study and in an expanded panel of SSc patients (20 patients) and healthy controls (20 subjects). Bars indicate SD. Figure S2. Expression of selected genes modulated in SSc patients and regulated by miRNAs targeted by ncRNA00201. Bars indicate SD. Figure S3. Serum levels of selected molecules in SSc patients and in normal subjects. The histograms represent the mean of the results obtained in 20 healthy donors and in 20 SSc patients. Mann-Whitney Test was used to compare the two groups means.

Author Contributions

Conceptualization, M.D. and A.P.; Formal analysis, M.D. and E.T.; Investigation, M.D.; Resources, E.T.; Supervision, A.P. and C.L.; Validation, M.D.; Writing—original draft, M.D. and A.P.; Writing—review and editing, A.P. and C.L.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Denton, C.P.; Khanna, D. Systemic sclerosis. Lancet 2017, 390, 1685–1699. [Google Scholar] [CrossRef]
  2. Lunardi, C.; Bason, C.; Navone, R.; Millo, E.; Damonte, G.; Corrocher, R.; Puccetti, A. Systemic sclerosis immunoglobulin G autoantibodies bind the human cytomegalovirus late protein UL94 and induce apoptosis in human endothelial cells. Nat. Med. 2000, 6, 1183–1186. [Google Scholar] [CrossRef] [PubMed]
  3. Dolcino, M.; Puccetti, A.; Barbieri, A.; Bason, C.; Tinazzi, E.; Ottria, A.; Patuzzo, G.; Martinelli, N.; Lunardi, C. Infections and autoimmunity: Role of human cytomegalovirus in autoimmune endothelial cell damage. Lupus 2015, 24, 419–432. [Google Scholar] [CrossRef] [PubMed]
  4. Bergmann, C.; Distler, J.H. Epigenetic factors as drivers of fibrosis in systemic sclerosis. Epigenomics 2017, 9, 463–477. [Google Scholar] [CrossRef] [PubMed]
  5. Aslani, S.; Sobhani, S.; Gharibdoost, F.; Jamshidi, A.; Mahmoudi, M. Epigenetics and pathogenesis of systemic sclerosis; the ins and outs. Hum. Immunol. 2018, 79, 178–187. [Google Scholar] [CrossRef] [PubMed]
  6. Dolcino, M.; Pelosi, A.; Fiore, P.F.; Patuzzo, G.; Tinazzi, E.; Lunardi, C.; Puccetti, A. Gene profiling in patients with systemic sclerosis reveals the presence of oncogenic gene signatures. Front. Immunol. 2018, 9, 449. [Google Scholar] [CrossRef] [PubMed]
  7. Bernal-Bello, D.; de Tena, J.G.; Guillén-Del Castillo, A.; Selva-O’Callaghan, A.; Callejas-Moraga, E.L.; Marín-Sánchez, A.M.; Fonollosa-Pla, V.; Simeón-Aznar, C.P. Novel risk factors related to cancer in scleroderma. Autoimmun. Rev. 2017, 16, 461–468. [Google Scholar] [CrossRef] [PubMed]
  8. Shah, A.A.; Xu, G.; Rosen, A.; Hummers, L.K.; Wigley, F.M.; Elledge, S.J.; Casciola-Rosen, L. Brief Report: Anti-RNPC-3 Antibodies As a Marker of Cancer-Associated Scleroderma. Arthritis Rheumatol. 2017, 69, 1306–1312. [Google Scholar] [CrossRef] [PubMed]
  9. Monfort, J.B.; Lazareth, I.; Priollet, P. Paraneoplastic systemic sclerosis: About 3 cases and review of literature. J. Mal. Vasc. 2016, 41, 365–370. [Google Scholar] [CrossRef] [PubMed]
  10. Shah, A.A.; Casciola-Rosen, L. Cancer and scleroderma: A paraneoplastic disease with implications for malignancy screening. Curr. Opin. Rheumatol. 2015, 27, 563–570. [Google Scholar] [CrossRef] [PubMed]
  11. van den Hoogen, F.; Khanna, D.; Fransen, J.; Johnson, S.R.; Baron, M.; Tyndall, A.; Matucci-Cerinic, M.; Naden, R.P.; Medsger, T.A., Jr.; Carreira, P.E.; et al. 2013 classification criteria for systemic sclerosis: An American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis. Rheum. 2013, 65, 2737–2747. [Google Scholar] [CrossRef] [PubMed]
  12. LeRoy, E.C.; Black, C.; Fleischmajer, R.; Jablonska, S.; Krieg, T.; Medsger, T.A., Jr.; Rowell, N.; Wollheim, F. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J. Rheumatol. 1988, 15, 202–205. [Google Scholar] [PubMed]
  13. Melsens, K.; De Keyser, F.; Decuman, S.; Piette, Y.; Vandecasteele, E.; Smith, V. Disease activity indices in systemic sclerosis: A systematic literature review. Clin. Exp. Rheumatol. 2016, 34, 186–192. [Google Scholar] [PubMed]
  14. Li, J.H.; Liu, S.; Zhou, H.; Qu, L.H.; Yang, J.H. StarBase v2.0: Decoding miRNA-ceRNA, miRNA-ncRNA and protein-RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014, 42, D92–D97. [Google Scholar] [CrossRef] [PubMed]
  15. Pathan, M.; Keerthikumar, S.; Ang, C.S.; Gangoda, L.; Quek, C.Y.; Williamson, N.A.; Mouradov, D.; Sieber, O.M.; Simpson, R.J.; Salim, A.; et al. Funrich: An open access standalone functional enrichment and interaction network analysis tool. Proteomics 2015, 15, 2597–2601. [Google Scholar] [CrossRef] [PubMed]
  16. Jensen, L.J.; Kuhn, M.; Stark, M.; Chaffron, S.; Creevey, C.; Muller, J.; Doerks, T.; Julien, P.; Roth, A.; Simonovic, M.; et al. String 8—A global view on proteins and their functional interactions in 630 organisms. Nucleic Acids Res. 2009, 37, D412–D416. [Google Scholar] [CrossRef] [PubMed]
  17. Cline, M.S.; Smoot, M.; Cerami, E.; Kuchinsky, A.; Landys, N.; Workman, C.; Christmas, R.; Avila-Campilo, I.; Creech, M.; Gross, B.; et al. Integration of biological networks and gene expression data using cytoscape. Nat. Protoc. 2007, 2, 2366–2382. [Google Scholar] [CrossRef] [PubMed]
  18. Mi, H.; Muruganujan, A.; Casagrande, J.T.; Thomas, P.D. Large-scale gene function analysis with the PANTHER classification system. Nat. Protoc. 2013, 8, 1551–1566. [Google Scholar] [CrossRef] [PubMed]
  19. Sutaria, D.S.; Jiang, J.; Azevedo-Pouly, A.C.P.; Lee, E.J.; Lerner, M.R.; Brackett, D.J.; Vandesompele, J.; Mestdagh, P.; Schmittgen, T.D. Expression profiling identifies the noncoding processed transcript of HNRNPU with proliferative properties in pancreatic ductal adenocarcinoma. Noncoding RNA 2017, 3, 24. [Google Scholar] [CrossRef] [PubMed]
  20. Skaug, B.; Assassi, S. Type I interferon dysregulation in systemic sclerosis. Cytokine 2019. [Google Scholar] [CrossRef] [PubMed]
  21. Asano, Y.; Sato, S. Vasculopathy in scleroderma. Semin. Immunopathol. 2015, 37, 489–500. [Google Scholar] [CrossRef] [PubMed]
  22. Overbeek, M.J.; Boonstra, A.; Voskuyl, A.E.; Vonk, M.C.; Vonk-Noordegraaf, A.; van Berkel, M.P.; Mooi, W.J.; Dijkmans, B.A.; Hondema, L.S.; Smit, E.F.; et al. Platelet-derived growth factor receptor-β and epidermal growth factor receptor in pulmonary vasculature of systemic sclerosis-associated pulmonary arterial hypertension versus idiopathic pulmonary arterial hypertension and pulmonary veno-occlusive disease: A case-control study. Arthritis Res. Ther. 2011, 13, R61. [Google Scholar] [CrossRef] [PubMed]
  23. Yamane, K.; Ihn, H.; Tamaki, K. Epidermal growth factor up-regulates expression of transforming growth factor beta receptor type II in human dermal fibroblasts by phosphoinositide 3-kinase/Akt signaling pathway: Resistance to epidermal growth factor stimulation in scleroderma fibroblasts. Arthritis Rheum. 2003, 48, 1652–1666. [Google Scholar] [CrossRef] [PubMed]
  24. Tan, F.K.; Zhou, X.; Mayes, M.D.; Gourh, P.; Guo, X.; Marcum, C.; Jin, L.; Arnett, F.C., Jr. Signatures of differentially regulated interferon gene expression and vasculotrophism in the peripheral blood cells of systemic sclerosis patients. Rheumatology 2006, 45, 694–702. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  25. Stanek, D.; Vencovský, J.; Kafková, J.; Raska, I. Heterogenous nuclear RNP C1 and C2 core proteins are targets for an autoantibody found in the serum of a patient with systemic sclerosis and psoriatic arthritis. Arthritis Rheum. 1997, 40, 2172–2177. [Google Scholar] [PubMed]
  26. Yang, S.J.; Yang, S.Y.; Wang, D.D.; Chen, X.; Shen, H.Y.; Zhang, X.H.; Zhong, S.L.; Tang, J.H.; Zhao, J.H. The miR-30 family: Versatile players in breast cancer. Tumor Biol. 2017, 39, 1010428317692204. [Google Scholar] [CrossRef] [PubMed]
  27. Watt, K.; Newsted, D.; Voorand, E.; Gooding, R.J.; Majewski, A.; Truesdell, P.; Yao, B.; Tuschl, T.; Renwick, N.; Craig, A.W. MicroRNA-206 suppresses TGF-β signalling to limit tumor growth and metastasis in lung adenocarcinoma. Cell. Signal. 2018, 50, 25–36. [Google Scholar] [CrossRef] [PubMed]
  28. Wermuth, P.J.; Piera-Velazquez, S.; Rosenbloom, J.; Jimenez, S.A. Existing and novel biomarkers for precision medicine in systemic sclerosis. Nat. Rev. Rheumatol. 2018, 14, 421–432. [Google Scholar] [CrossRef] [PubMed]
  29. Hersi, H.M.; Raulf, N.; Gaken, J.; Folarin, N.; Tavassoli, M. MicroRNA-9 inhibits growth and invasion of head and neck cancer cells and is a predictive biomarker of response to plerixafor, an inhibitor of its target CXCR4. Mol. Oncol. 2018, 12, 2023–2041. [Google Scholar] [CrossRef] [PubMed]
  30. Xiong, H.; Yan, T.; Zhang, W.; Shi, F.; Jiang, X.; Wang, X.; Li, S.; Chen, Y.; Chen, C.; Zhu, Y. miR-613 inhibits cell migration and invasion by downregulating Daam1 in triple-negative breast cancer. Cell. Signal. 2018, 44, 33–42. [Google Scholar] [CrossRef] [PubMed]
  31. Zhao, L.; Wang, Y.; Jiang, L.; He, M.; Bai, X.; Yu, L.; Wei, M. MiR-302a/b/c/d cooperatively sensitizes breast cancer cells to adriamycin via suppressing P-glycoprotein(P-gp) by targeting MAP/ERK kinase kinase 1 (MEKK1). J. Exp. Clin. Cancer Res. 2016, 35, 25. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  32. Chen, X.; Xu, Y.; Liao, X.; Liao, R.; Zhang, L.; Niu, K.; Li, T.; Li, D.; Chen, Z.; Duan, Y.; et al. Plasma miRNAs in predicting radiosensitivity in non-small cell lung cancer. Tumor Biol. 2016, 37, 11927–11936. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  33. Wang, Q.; Liu, S.; Zhao, X.; Zhao, X.; Wang, Y.; Tian, D.; Jiang, W. MiR-372-3p promotes cell growth and metastasis by targeting FGF9 in lung squamous cell carcinoma. Cancer Med. 2017, 6, 1323–1330. [Google Scholar] [CrossRef] [PubMed]
  34. Zhou, B.; Zuo, X.X.; Li, Y.S.; Gao, S.M.; Dai, X.D.; Zhu, H.L.; Luo, H. Integration of microRNA and mRNA expression profiles in the skin of systemic sclerosis patients. Sci. Rep. 2017, 7, 42899. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  35. Lv, C.; Li, F.; Li, X.; Tian, Y.; Zhang, Y.; Sheng, X.; Song, Y.; Meng, Q.; Yuan, S.; Luan, L.; et al. MiR-31 promotes mammary stem cell expansion and breast tumorigenesis by suppressing Wnt signaling antagonists. Nat. Commun. 2017, 8, 1036. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  36. Li, J.; Wei, J.; Mei, Z.; Yin, Y.; Li, Y.; Lu, M.; Jin, S. Suppressing role of miR-520a-3p in breast cancer through CCND1 and CD44. Am. J. Transl. Res. 2017, 9, 146–154. [Google Scholar] [PubMed]
  37. Hu, N.; Zhang, J.; Cui, W.; Kong, G.; Zhang, S.; Yue, L.; Bai, X.; Zhang, Z.; Zhang, W.; Zhang, X.; et al. miR-520b regulates migration of breast cancer cells by targeting hepatitis B X-interacting protein and interleukin-8. J. Biol. Chem. 2011, 286, 13714–13722. [Google Scholar] [CrossRef] [PubMed]
  38. Guan, R.; Cai, S.; Sun, M.; Xu, M. Upregulation of miR-520b promotes ovarian cancer growth. Oncol. Lett. 2017, 14, 3155–3161. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  39. Tang, C.P.; Zhou, H.J.; Qin, J.; Luo, Y.; Zhang, T. MicroRNA-520c-3p negatively regulates EMT by targeting IL-8 to suppress the invasion and migration of breast cancer. Oncol. Rep. 2017, 38, 3144–3152. [Google Scholar] [CrossRef] [PubMed]
  40. Ren, Z.; Yang, T.; Ding, J.; Liu, W.; Meng, X.; Zhang, P.; Liu, K.; Wang, P. MiR-520d-3p antitumor activity in human breast cancer via post-transcriptional regulation of spindle and kinetochore associated 2 expression. Am. J. Transl. Res. 2018, 10, 1097–1108. [Google Scholar] [PubMed]
  41. Yi, M.; Li, M.; Long, X.; Ye, J.; Cui, J.; Wei, W.; Wan, H.; Yin, M.; Gao, S.; Su, Z.; et al. miR-520e regulates cell proliferation, apoptosis and migration in breast cancer. Oncol. Lett. 2016, 12, 3543–3548. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  42. Weng, H.; Lal, K.; Yang, F.F.; Chen, J. The pathological role and prognostic impact of miR-181 in acute myeloid leukemia. Cancer Genet. 2015, 208, 225–229. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  43. Guo, X.; Zhu, Y.; Hong, X.; Zhang, M.; Qiu, X.; Wang, Z.; Qi, Z.; Hong, X. miR-181d and c-myc-mediated inhibition of CRY2 and FBXL3 reprograms metabolism in colorectal cancer. Cell Death Dis. 2017, 8, e2958. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  44. Khalil, S.; Fabbri, E.; Santangelo, A.; Bezzerri, V.; Cantù, C.; Di Gennaro, G.; Finotti, A.; Ghimenton, C.; Eccher, A.; Dechecchi, M.; et al. miRNA array screening reveals cooperative MGMT-regulation between miR-181d-5p and miR-409-3p in glioblastoma. Oncotarget 2016, 7, 28195–28206. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  45. Li, Y.; Kuscu, C.; Banach, A.; Zhang, Q.; Pulkoski-Gross, A.; Kim, D.; Liu, J.; Roth, E.; Li, E.; Shroyer, K.R.; et al. miR-181a-5p inhibits cancer cell migration and angiogenesis via downregulation of matrix metalloproteinase-14. Cancer Res. 2015, 75, 2674–2685. [Google Scholar] [CrossRef] [PubMed]
  46. Liu, X.; Peng, H.; Liao, W.; Luo, A.; Cai, M.; He, J.; Zhang, X.; Luo, Z.; Jiang, H.; Xu, L. MiR-181a/b induce the growth, invasion, and metastasis of neuroblastoma cells through targeting ABI1. Mol. Carcinog. 2018, 57, 1237–1250. [Google Scholar] [CrossRef] [PubMed]
  47. Liu, H.N.; Qie, P.; Yang, G.; Song, Y.B. miR-181b inhibits chemoresistance in cisplatin-resistant H446 small cell lung cancer cells by targeting Bcl-2. Arch. Med. Sci. 2018, 14, 745–751. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  48. Kawano, M.; Tanaka, K.; Itonaga, I.; Iwasaki, T.; Tsumura, H. MicroRNA-181c prevents apoptosis by targeting of FAS receptor in Ewing’s sarcoma cells. Cancer Cell. Int. 2018, 18, 37. [Google Scholar] [CrossRef] [PubMed]
  49. Quan, J.; Pan, X.; He, T.; Lin, C.; Lai, Y.; Chen, P.; Zhang, Z.; Yang, S.; Wang, T.; Lai, Y. Tumor suppressor miR-211-5p is associated with cellular migration, proliferation and apoptosis in renal cell carcinoma. Exp. Ther. Med. 2018, 15, 4019–4028. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  50. Jiang, G.; Wen, L.; Deng, W.; Jian, Z.; Zheng, H. Regulatory role of miR-211-5p in hepatocellular carcinoma metastasis by targeting ZEB2. Biomed. Pharmacother. 2017, 90, 806–812. [Google Scholar] [CrossRef] [PubMed]
  51. Chen, L.L.; Zhang, Z.J.; Yi, Z.B.; Li, J.J. MicroRNA-211-5p suppresses tumour cell proliferation, invasion, migration and metastasis in triple-negative breast cancer by directly targeting SETBP1. Br. J. Cancer. 2017, 117, 78–88. [Google Scholar] [CrossRef] [PubMed]
  52. Díaz-Martínez, M.; Benito-Jardón, L.; Alonso, L.; Koetz-Ploch, L.; Hernando, E.; Teixidó, J. miR-204-5p and miR-211-5p Contribute to BRAF Inhibitor Resistance in Melanoma. Cancer Res. 2018, 78, 1017–1030. [Google Scholar] [CrossRef] [PubMed]
  53. Ye, Z.H.; Wen, D.Y.; Cai, X.Y.; Liang, L.; Wu, P.R.; Qin, H.; Yang, H.; He, Y.; Chen, G. The protective value of miR-204-5p for prognosis and its potential gene network in various malignancies: A comprehensive exploration based on RNA-seq high-throughput data and bioinformatics. Oncotarget 2017, 8, 104960–104980. [Google Scholar] [CrossRef] [PubMed]
  54. Gallo, L.H.; Ko, J.; Donoghue, D.J. The importance of regulatory ubiquitination in cancer and metastasis. Cell Cycle 2017, 16, 634–648. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  55. Jack, J.; Small, G.W.; Brown, C.C.; Havener, T.M.; McLeod, H.L.; Motsinger-Reif, A.A.; Richards, K.L. Gene expression and linkage analysis implicate CBLB as a mediator of rituximab resistance. Pharmacogenomics J. 2018, 18, 467–473. [Google Scholar] [CrossRef] [PubMed]
  56. Hwang, I.Y.; Park, C.; Harrison, K.; Boularan, C.; Galés, C.; Kehrl, J.H. An essential role for RGS protein/Gαi2 interactions in B lymphocyte-directed cell migration and trafficking. J. Immunol. 2015, 194, 2128–2139. [Google Scholar] [CrossRef] [PubMed]
  57. Crescioli, C.; Corinaldesi, C.; Riccieri, V.; Raparelli, V.; Vasile, M.; Del Galdo, F.; Valesini, G.; Lenzi, A.; Basili, S.; Antinozzi, C. Association of circulating CXCL10 and CXCL11 with systemic sclerosis. Ann. Rheum. Dis. 2018, 77, 1845–1846. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  58. Ruggiero, C.; Fragassi, G.; Grossi, M.; Picciani, B.; Di Martino, R.; Capitani, M.; Buccione, R.; Luini, A.; Sallese, M.A. Golgi-based KDELR-dependent signalling pathway controls extracellular matrix degradation. Oncotarget 2015, 6, 3375–3393. [Google Scholar] [CrossRef] [PubMed]
  59. Mahil, S.K.; Twelves, S.; Farkas, K.; Setta-Kaffetzi, N.; Burden, A.D.; Gach, J.E.; Irvine, A.D.; Képíró, L.; Mockenhaupt, M.; Oon, H.H.; et al. AP1S3 mutations cause skin autoinflammation by disrupting keratinocyte autophagy and up-regulating IL-36 production. J. Invest. Dermatol. 2016, 136, 2251–2259. [Google Scholar] [CrossRef] [PubMed]
  60. Douglas, G.; Hale, A.B.; Patel, J.; Chuaiphichai, S.; Al Haj Zen, A.; Rashbrook, V.S.; Trelfa, L.; Crabtree, M.J.; McNeill, E.; Channon, K.M. Roles for endothelial cell and macrophage Gch1 and tetrahydrobiopterin in atherosclerosis progression. Cardiovasc. Res. 2018, 114, 1385–1399. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  61. Chuaiphichai, S.; Crabtree, M.J.; Mcneill, E.; Hale, A.B.; Trelfa, L.; Channon, K.M.; Douglas, G.A. Key role for tetrahydrobiopterin-dependent endothelial NOS regulation in resistance arteries: Studies in endothelial cell tetrahydrobiopterin-deficient mice. Br. J. Pharmacol. 2017, 174, 657–671. [Google Scholar] [CrossRef] [PubMed]
  62. Wallace, S.; Guo, D.C.; Regalado, E.; Mellor-Crummey, L.; Bamshad, M.; Nickerson, D.A.; Dauser, R.; Hanchard, N.; Marom, R.; Martin, E.; et al. Disrupted nitric oxide signaling due to GUCY1A3 mutations increases risk for moyamoya disease, achalasia and hypertension. Clin. Genet. 2016, 90, 351–360. [Google Scholar] [CrossRef] [PubMed]
  63. Giampaolo, S.; Wójcik, G.; Klein-Hessling, S.; Serfling, E.; Patra, A.K. B cell development is critically dependent on NFATc1 activity. Cell. Mol. Immunol. 2018. [Google Scholar] [CrossRef] [PubMed]
  64. Cobaleda, C.; Schebesta, A.; Delogu, A.; Busslinger, M. Pax5: The guardian of B cell identity and function. Nat. Immunol. 2007, 8, 463–470. [Google Scholar] [CrossRef] [PubMed]
  65. Allanore, Y.; Wipff, J.; Kahan, A.; Boileau, C. Genetic basis for systemic sclerosis. Joint Bone Spine 2007, 74, 577–583. [Google Scholar] [CrossRef] [PubMed]
  66. Zhou, X.; Tan, F.K.; Guo, X.; Arnett, F.C. Attenuation of collagen production with small interfering RNA of SPARC in cultured fibroblasts from the skin of patients with scleroderma. Arthritis Rheum. 2006, 54, 2626–2631. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  67. Butler, M.J.; Aguiar, R.C.T. Biology informs treatment choices in diffuse large B cell lymphoma. Trends Cancer 2017, 3, 871–882. [Google Scholar] [CrossRef] [PubMed]
  68. Groettrup, M.; Kirk, C.J.; Basler, M. Proteasomes in immune cells: More than peptide producers? Nat. Rev. Immunol. 2010, 10, 73–78. [Google Scholar] [CrossRef] [PubMed]
  69. Wu, G.C.; Pan, H.F.; Leng, R.X.; Wang, D.G.; Li, X.P.; Li, X.M.; Ye, D.Q. Emerging role of long noncoding RNAs in autoimmune diseases. Autoimmun. Rev. 2015, 14, 798–805. [Google Scholar] [CrossRef] [PubMed]
  70. Dolcino, M.; Pelosi, A.; Fiore, P.F.; Patuzzo, G.; Tinazzi, E.; Lunardi, C.; Puccetti, A. Long non-coding RNAs play a role in the pathogenesis of psoriatic arthritis by regulating microRNAs and genes involved in inflammation and metabolic syndrome. Front. Immunol. 2018, 9, 1533. [Google Scholar] [CrossRef] [PubMed]
  71. Planque, S.; Zhou, Y.X.; Nishiyama, Y.; Sinha, M.; O’Connor-Mccourt, M.; Arnett, F.C.; Paul, S. Autoantibodies to the epidermal growth factor receptor in systemic sclerosis, lupus, and autoimmune mice. FASEB J. 2003, 17, 136–143. [Google Scholar] [CrossRef] [PubMed]
  72. Normanno, N.; De Luca, A.; Bianco, C.; Strizzi, L.; Mancino, M.; Maiello, M.R.; Carotenuto, A.; De Feo, G.; Caponigro, F.; Salomon, D.S. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 2006, 366, 2–16. [Google Scholar] [CrossRef] [PubMed]
  73. Pattanaik, D.; Postlethwaite, A.E. A role for lysophosphatidic acid and sphingosine 1-phosphate in the pathogenesis of systemic sclerosis. Discov. Med. 2010, 10, 61–67. [Google Scholar]
  74. Watters, R.J.; Wang, H.G.; Sung, S.S.; Loughran, T.P.; Liu, X. Targeting sphingosine-1-phosphate receptors in cancer. Anticancer Agents Med. Chem. 2011, 11, 810–817. [Google Scholar] [CrossRef] [PubMed]
  75. Daher, Z.; Noël, J.; Claing, A. Endothelin-1 promotes migration of endothelial cells through the activation of ARF6 and the regulation of FAK activity. Cell. Signal. 2008, 20, 2256–2265. [Google Scholar] [CrossRef] [PubMed]
  76. Hongu, T.; Yamauchi, Y.; Funakoshi, Y.; Katagiri, N.; Ohbayashi, N.; Kanaho, Y. Pathological functions of the small GTPase Arf6 in cancer progression: Tumor angiogenesis and metastasis. Small GTPases 2016, 7, 47–53. [Google Scholar] [CrossRef] [PubMed]
  77. Morris, E.; Chrobak, I.; Bujor, A.; Hant, F.; Mummery, C.; Ten Dijke, P.; Trojanowska, M. Endoglin promotes TGF-β/Smad1 signaling in scleroderma fibroblasts. J. Cell. Physiol. 2011, 226, 3340–3348. [Google Scholar] [CrossRef] [PubMed]
  78. Cunha, S.I.; Pietras, K. ALK1 as an emerging target for antiangiogenic therapy of cancer. Blood 2011, 117, 6999–7006. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  79. Bagnato, A.; Loizidou, M.; Pflug, B.R.; Curwen, J.; Growcott, J. Role of the endothelin axis and its antagonists in the treatment of cancer. Br. J. Pharmacol. 2011, 163, 220–233. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  80. Porter, A.P.; Papaioannou, A.; Malliri, A. Deregulation of Rho GTPases in cancer. Small GTPases 2016, 7, 123–138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  81. Tsou, P.S.; Amin, M.A.; Campbell, P.L.; Zakhem, G.; Balogh, B.; Edhayan, G.; Ohara, R.A.; Schiopu, E.; Khanna, D.; Koch, A.E.; et al. Activation of the thromboxane A2 receptorby 8-isoprostane inhibits the pro-angiogenic effect of vascular endothelial growth factor in scleroderma. J. Invest. Dermatol. 2015, 135, 3153–3162. [Google Scholar] [CrossRef] [PubMed]
  82. Asano, Y.; Ihn, H.; Yamane, K.; Jinnin, M.; Mimura, Y.; Tamaki, K. Phosphatidylinositol3-kinase is involved in alpha2(I) collagen gene expression in normal and scleroderma fibroblasts. J. Immunol. 2004, 172, 7123–7135. [Google Scholar] [CrossRef] [PubMed]
  83. Laplante, P.; Raymond, M.A.; Gagnon, G.; Vigneault, N.; Sasseville, A.M.; Langelier, Y.; Bernard, M.; Raymond, Y.; Hébert, M.J. Novel fibrogenic pathways are activated in response to endothelial apoptosis: Implications in the pathophysiology of systemic sclerosis. J. Immunol. 2005, 174, 5740–5749. [Google Scholar] [CrossRef] [PubMed]
  84. Pópulo, H.; Lopes, J.M.; Soares, P. The mTOR signalling pathway in human cancer. Int. J. Mol. Sci. 2012, 13, 1886–1918. [Google Scholar] [CrossRef] [PubMed]
  85. Mitra, A.; Luna, J.I.; Marusina, A.I.; Merleev, A.; Kundu-Raychaudhuri, S.; Fiorentino, D.; Raychaudhuri, S.P.; Maverakis, E. Dual mTOR Inhibition is required to prevent TGF-β-mediated fibrosis: Implications for scleroderma. J. Invest. Dermatol. 2015, 135, 2873–2876. [Google Scholar] [CrossRef] [PubMed]
  86. Ihn, H.; Yamane, K.; Tamaki, K. Increased phosphorylation and activation of mitogen-activated protein kinase p38 in scleroderma fibroblasts. J. Invest. Dermatol. 2005, 125, 247–255. [Google Scholar] [CrossRef] [PubMed]
  87. Leask, A. Getting out of a sticky situation: Targeting the myofibroblast inscleroderma. Open Rheumatol. J. 2012, 6, 163–169. [Google Scholar] [CrossRef] [PubMed]
  88. Corre, I.; Paris, F.; Huot, J. The p38 pathway, a major pleiotropic cascade that transduces stress and metastatic signals in endothelial cells. Oncotarget 2017, 8, 55684–55714. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  89. Lou, S.; Wang, P.; Yang, J.; Ma, J.; Liu, C.; Zhou, M. Prognostic and clinicopathological value of Rac1 in cancer survival: Evidence from a meta-analysis. J. Cancer 2018, 9, 2571–2579. [Google Scholar] [CrossRef] [PubMed]
  90. Furler, R.L.; Nixon, D.F.; Brantner, C.A.; Popratiloff, A.; Uittenbogaart, C.H. TGF-β sustains tumor progression through biochemical and mechanical signal transduction. Cancers (Basel) 2018, 10, 199. [Google Scholar] [CrossRef] [PubMed]
  91. Wei, J.; Bhattacharyya, S.; Tourtellotte, W.G.; Varga, J. Fibrosis in systemic sclerosis: Emerging concepts and implications for targeted therapy. Autoimmun. Rev. 2011, 10, 267–275. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  92. Ciechomska, M.; Cant, R.; Finnigan, J.; van Laar, J.M.; O’Reilly, S. Role of toll-like receptors in systemic sclerosis. Expert Rev. Mol. Med. 2013, 15, e9. [Google Scholar] [CrossRef] [PubMed]
  93. Rakoff-Nahoum, S.; Medzhitov, R. Toll-like receptors and cancer. Nat. Rev. Cancer 2009, 9, 57–63. [Google Scholar] [CrossRef] [PubMed]
Jcm 08 00320 g001 550
Figure 1. Degree Sorted Circle Layout of the Protein–Protein Interaction (PPI) network of differentially expressed genes in Systemic Sclerosis patients. Nodes are ordered around a circle based on their degree of connectivity (number of edges). Genes not targeted, genes targeted but not included in modules and genes targeted and included in the modules are differently colored.
Figure 1. Degree Sorted Circle Layout of the Protein–Protein Interaction (PPI) network of differentially expressed genes in Systemic Sclerosis patients. Nodes are ordered around a circle based on their degree of connectivity (number of edges). Genes not targeted, genes targeted but not included in modules and genes targeted and included in the modules are differently colored.
Jcm 08 00320 g001
Jcm 08 00320 g002 550
Figure 2. Schematic representation of enriched (p < 0.05) signaling pathways modulated by selected micro RNAs (miRNAs) that are targeted by non-coding RNA 201 (ncRNA00201). Pathways are grouped by their relevance to the disease features including immune and inflammatory response, vasculitis and fibrosis.
Figure 2. Schematic representation of enriched (p < 0.05) signaling pathways modulated by selected micro RNAs (miRNAs) that are targeted by non-coding RNA 201 (ncRNA00201). Pathways are grouped by their relevance to the disease features including immune and inflammatory response, vasculitis and fibrosis.
Jcm 08 00320 g002
Jcm 08 00320 g003 550
Figure 3. Schematic representation of enriched (p < 0.05) signaling pathways modulated by selected miRNAs that are targeted by ncRNA00201. Selection of enriched pathways that are both involved in Systemic Sclerosis (SSc) and in cancer development. Enrichment p-values are showed in brackets.
Figure 3. Schematic representation of enriched (p < 0.05) signaling pathways modulated by selected miRNAs that are targeted by ncRNA00201. Selection of enriched pathways that are both involved in Systemic Sclerosis (SSc) and in cancer development. Enrichment p-values are showed in brackets.
Jcm 08 00320 g003
Table
Table 1. Demographic and clinical and features of patients and healthy subjects enrolled in the study.
Table 1. Demographic and clinical and features of patients and healthy subjects enrolled in the study.
Demographic and Clinical Features of Systemic Sclerosis Patients and Healthy Controls
Healthy controls 20
Male/Female3/17
Mean age (years)55 ± 11
Patients lSScdSSc
1010
Male/Female2/81/9
Mean age (years)57 ± 1355 ± 10
Laboratory findingsANA9 (90%)10 (100%)
Anti-centromere6 (60%)2 (20%)
Scl-7008 (80%)
Lung involvementInterstitial disease3 (30%)6 (60%)
Pulmonary arterial hypertension2 (20%)1 (10%)
Skin involvementmRSS8 ± 314 ± 8
Digital ulcers3 (30%)5 (50%)
Video CapillaroscopyEarly2 (20%)3 (30%)
Active5 (50%)4 (40%)
Late3 (30%)3 (30%)
Kidney involvement 0 (0%)1 (10%)
Gastro-intestinal involvement 7 (70%)9 (90%)
lSSc = limited Systemic Sclerosis; dSSc = diffuse Systemic Sclerosis; ANA = anti-nuclear antibody; Scl-70 = Sclero-70; mRSS = modified Rodnam Skin Score.
Table
Table 2. Selection of significantly differentially expressed genes and lncRNA in Systemic Sclerosis patients versus healthy subjects.
Table 2. Selection of significantly differentially expressed genes and lncRNA in Systemic Sclerosis patients versus healthy subjects.
IDFold Changep-ValueGene SymbolDescriptionAccession Number
TC0100018570.hg.1−1.80.0003ncRNA00201heterogeneous nuclear ribonucleoprotein U antisense RNA 1ENST00000366527.3
Apoptosis
TC0100013000.hg.11.570.0012CASP9caspase 9AB020979.1
TC1000007990.hg.12.320.0017DDIT4DNA damage inducible transcript 4NM_019058.3
TC1900011729.hg.12.1<0.0001TIMM50translocase of inner mitochondrial membrane 50 homolog NM_001001563.3
TC0600014045.hg.11.650.0064PDCD2programmed cell death 2NM_002598.3
TC1800008891.hg.12.10.0013BCL2B-cell CLL/lymphoma 2NM_000633.2
TC0200010972.hg.11.680.0003MFFmitochondrial fission factorNM_001277061.1
TC1500008231.hg.11.810.0002AENapoptosis enhancing nucleaseNM_022767.3
TC0500010104.hg.11.630.0006DAPdeath-associated proteinNM_001291963.1
Immune Response
TC0300013859.hg.12.950.0015CD200CD200 moleculeNM_005944.6
TC2000007519.hg.11.590.009CD40CD40 molecule, TNF receptor superfamily member 5NM_001250.5
TC1900008166.hg.13.550.0029CD79ACD79a molecule, immunoglobulin-associated alphaL32754.1
TC1700011430.hg.12.610.0011CD79BCD79b molecule, immunoglobulin-associated betaKM057839
TC0700009461.hg.12.770.0008TRBV24-1T cell receptor beta variable 24-1AY373826
TC0600007597.hg.11.590.0039LST1leukocyte specific transcript 1NM_007161
TC1600011368.hg.120.0002LATlinker for activation of T-cellsAF036905
TC1400010806.hg.16.890.0029IGHV5-51immunoglobulin heavy variable 5-51EU433880.1
TC1600007312.hg.12.49<0.0001IL4Rinterleukin 4 receptorAF421855.1
Inflammatory Response
TC0400011053.hg.19.890.0001CXCL10chemokine (C-X-C motif) ligand 10NM_001565.3
TC0400011054.hg.12.110.0029CXCL11chemokine (C-X-C motif) ligand 11NM_020639.2
TC1100009225.hg.12.560.0068CXCR5chemokine (C-X-C motif) receptor 5NM_032966.2
TC0900008660.hg.11.720.0027PTGS1prostaglandin-endoperoxide synthase 1 NM_001271367.1
TC0500007231.hg.12.420.0002PTGER4prostaglandin E receptor 4 (subtype EP4)NM_000958.2
TC2200009231.hg.11.680.0004MIFmacrophage migration inhibitory factor NM_002415.1
TC0300011059.hg.12.060.0002GPX1glutathione peroxidase 1M21304.1
TC1400007752.hg.11.940.008GSTZ1glutathione S-transferase zeta 1U86529.1
Cell Adhesion
TC1100012686.hg.12.70.0015ESAMendothelial cell adhesion moleculeNM_138961.2
TC1100009611.hg.14.790.0028JAM3junctional adhesion molecule 3AF448478.1
TC1100006494.hg.11.860.0023CD151CD151 molecule (Raph blood group)D29963.1
TC0100016357.hg.13.280.0008SELPselectin PNM_003005.3
TC1700011435.hg.11.780.0002ICAM2intercellular adhesion molecule 2NM_001099788.1
TC1900009625.hg.11.540.0052ICAM3intercellular adhesion molecule 3NM_002162.4
TC1300009165.hg.11.780.0025PCDH9protocadherin 9AF169692.2
TC1700012274.hg.17.810.0006ITGB3integrin beta 3NM_000212.2
Blood Coagulation
TC1100007938.hg.12.090.0007FERMT3fermitin family member 3XM_017018398.2
TC0600010709.hg.13.20.0065F13A1coagulation factor XIII, A1 polypeptideNM_000129.3
TC0100016828.hg.11.550.0027F13Bcoagulation factor XIII, B polypeptideNM_001994.2
TC0200015194.hg.12.290.0008TFPItissue factor pathway inhibitor NM_006287.5
TC0100008056.hg.11.860.0063MPLMPL proto-oncogene, thrombopoietin receptorNM_005373.2
TC2200006614.hg.12.880.0034GP1BBglycoprotein Ib (platelet), beta polypeptideNM_000407.4
TC1000008056.hg.12.420.0031VCLvinculinM33308.1
TC0700008582.hg.11.510.0008SERPINE1endothelial plasminogen activator inhibitor (PAI-1)NM_000602.4
Angiogenesis
TC0500012519.hg.14.740.0005SPARCsecreted protein, acidic, cysteine-rich (osteonectin)NM_000602.4
TC0400011053.hg.19.890.0001CXCL10chemokine (C-X-C motif) ligand 10NM_001565.3
TC1700012468.hg.11.740.0086HN1hematological and neurological expressed 1AF086910.2
TC1500010429.hg.11.910.0002CIB1calcium and integrin binding 1 (calmyrin)NM_001277764.1
TC1700012274.hg.17.810.0006ITGB3integrin beta 3NM_000212.2
TC0700009977.hg.11.760.0014PDGFAplatelet-derived growth factor alpha polypeptideNM_002607.5
TC1900011707.hg.11.620.0022GPIglucose-6-phosphate isomeraseNM_001184722.1
TC0700011770.hg.1−1.720.0003KRIT1KRIT1, ankyrin repeat containingU90268.1
Positive Regulation of Fibroblast Proliferation
TC1200010977.hg.11.530.0071CDK4cyclin-dependent kinase 4NM_000075.3
TC2200009231.hg.11.680.0004MIFmacrophage migration inhibitory factor NM_002415.1
TC0800008845.hg.12.140.0029MYCv-myc avian myelocytomatosis viral oncogene homologNM_002467.5
TC0700009977.hg.11.760.0014PDGFAplatelet-derived growth factor alpha polypeptideNM_002607.5
TC0100015864.hg.11.680.0021S100A6S100 calcium binding protein A6NM_014624.3
TC0600007847.hg.12.680.0032CDKN1Acyclin-dependent kinase inhibitor 1A (p21, Cip1)NM_000389
TC0600006873.hg.13.90.0005BMP6bone morphogenetic protein 6NM_001718.5
ECM Component and Organization
TC0400012213.hg.11.530.0072CTSKcathepsin KNM_001911.2
TC0500012519.hg.14.740.0005SPARCsecreted protein, acidic, cysteine-rich (osteonectin)J03040.1
TC1900006470.hg.11.830.0022BSGbasigin (Ok blood group)GU557065.1
TC0300007383.hg.11.60.0035DAG1dystroglycan 1 (dystrophin-associated glycoprotein 1)L19711.1
TC0600008462.hg.13.190.0037COL19A1collagen, type XIX, alpha 1NM_001858.5
TC0100010863.hg.11.670.0087LAMC1laminin, gamma 1 (formerly LAMB2)NM_002293.3
TC2000008678.hg.12.17<0.0001CST3cystatin CAH002668.2
Interferon Alpha/Beta Signaling
TC1200012708.hg.12.660.0007OAS12-5-oligoadenylate synthetase 1AY730627.1
TC0100015921.hg.11.92<0.0001ADARadenosine deaminase, RNA-specificNM_015841.4
TC1400010584.hg.11.570.0015IRF9interferon regulatory factor 9NM_006084.4
TC1500008232.hg.12.040.0002ISG20interferon stimulated exonuclease gene 20kDaNM_002201.5
TC0100013445.hg.13.30.0018IFI6interferon, alpha-inducible protein 6NM_002038.3
TC1700007931.hg.11.520.0078IFI35interferon-induced protein 35NM_001330230.1
TC1000008396.hg.16.080.0059IFIT2interferon-induced protein with tetratricopeptide repeats 2NM_001547.4
TC1000008401.hg.11.650.0037IFIT5interferon-induced protein with tetratricopeptide repeats 5NM_012420.2
IL6-Mediated Signaling Events
TC1300008688.hg.11.650.0072FOXO1forkhead box O1NM_002015.3
TC0700006890.hg.112.690.0044IL6interleukin 6NM_000600.4
TC1700011903.hg.12.030.0027SOCS3suppressor of cytokine signaling 3NM_003955.4
TC0800008845.hg.12.140.0029MYCv-myc avian myelocytomatosis viral oncogene homologNM_002467.5
TGF-Beta Receptor Signaling
TC0100017258.hg.11.750.0003BATF3basic leucine zipper transcription factor, ATF-like 3NM_018664.2
TC1800008891.hg.12.10.0013BCL2B-cell CLL/lymphoma 2NM_000633.2
TC0500013301.hg.12.690.0015DAB2Dab, mitogen-responsive phosphoprotein, homolog 2NM_001244871.1
TC1300008688.hg.11.650.0072FOXO1forkhead box O1NM_002015.3
TC1400009426.hg.11.850.0001MAXMYC associated factor XNM_002382.4
TC0500011418.hg.11.550.0053MEF2Cmyocyte enhancer factor 2CNM_002397.4
TC0600013126.hg.12.560.0005PTPRKprotein tyrosine phosphatase, receptor type, KNM_001291983.1
TC0100011533.hg.11.930.0076ATF3activating transcription factor 3AY426987.1
PDGFR-Beta Signaling Pathway
TC1000007990.hg.12.320.0017DDIT4DNA damage inducible transcript 4NM_019058.3
TC0300009916.hg.11.680.0009HES1hes family bHLH transcription factor 1Y07572.1
TC1900010009.hg.11.810.0021JUNDjun D proto-oncogeneX56681.1
TC0200008742.hg.12.260.0001NCK2NCK adaptor protein 2NM_003581.4
TC1500010757.hg.11.890.0082RAB11ARAB11A, member RAS oncogene familyAF000231.1
TC0300008735.hg.11.650.0014RAB7ARAB7A, member RAS oncogene familyNM_004637.5
TC0900010543.hg.11.80.0034TLE1transducin-like enhancer of split 1 (E(sp1) homologM99435.1
TC1000008056.hg.12.420.0031VCLvinculinM33308.1
VEGF and VEGFR Signaling Network
TC0300011899.hg.1−1.550.0038CBLBCbl proto-oncogene B, E3 ubiquitin protein ligaseNM_001321786.1
TC0600011809.hg.11.9<0.0001CCND3cyclin D3NM_001136017.3
TC1200010977.hg.11.530.0071CDK4cyclin-dependent kinase 4NM_000075.3
TC0500012938.hg.12.09<0.0001CLTBclathrin, light chain BM20470.1
TC0300011059.hg.12.060.0002GPX1glutathione peroxidase 1M21304.1
TC0200014790.hg.11.950.0009GRB14growth factor receptor bound protein 14L76687.1
TC0900012167.hg.11.810.0005GSNgelsolinNM_000177.4
TC0100014014.hg.11.530.0022PRDX1peroxiredoxin 1NM_002574.3
Proteoglycan Syndecan-Mediated Signaling Events
TC0600006873.hg.13.90.0005BMP6bone morphogenetic protein 6NM_001718.5
TC1900006470.hg.11.830.0022BSGbasigin (Ok blood group)D45131.1
TC0300007055.hg.14.540.0005CTDSPLCTD small phosphatase likeNM_001008392.1
TC0200014790.hg.11.950.0009GRB14growth factor receptor bound protein 14L76687.1
TC0200008742.hg.12.260.0001NCK2NCK adaptor protein 2AF047487.1
TC1100013140.hg.11.86<0.0001TAF10TATA-box binding protein associated factor 10NM_006284.3
TC0500007912.hg.1−1.580.005ZFYVE16zinc finger, FYVE domain containing 16BC030808.1
Endothelins Signaling Pathway
TC1000007990.hg.12.320.0017DDIT4DNA damage inducible transcript 4NM_019058.3
TC1900009991.hg.11.780.0055JAK3Janus kinase 3NM_000215.3
TC0300007432.hg.11.840.0029MAPKAPK3mitogen-activated protein kinase-activated protein kinase 3NM_001243926.1
TC2200008477.hg.11.790.0044PATZ1POZ (BTB) and AT hook containing zinc finger 1NM_174907.3
TC0600013126.hg.12.560.0005PTPRKprotein tyrosine phosphatase, receptor type, KNM_001135648.2
TC0100016357.hg.13.280.0008SELPselectin P (granule membrane protein 140kDa, antigen CD62)NM_003005.3
TC1000008056.hg.12.420.0031VCLvinculinM33308.1
EGF Receptor (ErbB1) Signaling Pathway
TC0300011899.hg.1−1.550.0038CBLBCbl proto-oncogene B, E3 ubiquitin protein ligaseNM_001321786.1
TC1200010977.hg.11.530.0071CDK4cyclin-dependent kinase 4NM_000075.3
TC0600011635.hg.11.870.0098FKBP5FK506 binding protein 5NM_004117.3
TC0300007410.hg.11.560.0005GNAI2G protein, alpha inhibiting activity polypeptide 2NM_002070.3
TC0100010863.hg.11.670.0087LAMC1laminin, gamma 1 (formerly LAMB2)NM_002293.3
TC0200007446.hg.11.670.0003PRKCEprotein kinase C, epsilonNM_005400.2
TC0700008582.hg.11.510.0008SERPINE1serpin peptidase inhibitor, clade E, member 1NM_000602.4
TC1800006937.hg.11.990.0013TAF4BTATA box binding protein (TBP)-associated factor, 105kDaNM_001293725.1
Table
Table 3. Selected miRNAs targeted by ncRNA00201.
Table 3. Selected miRNAs targeted by ncRNA00201.
Total Genes Targeted in Systemic SclerosisDiseaseReferencesGenes Targeted in Modules (M)
hsa-miR-30e-5p
22breast, lung and other cancers[26]M1 (UBE2F,SOCS3, UBE2J1) M2 (GNAI2)
hsa-miR-206
20lung cancer[27]M2 (CXCL11) M5 (GCH1)
hsa-miR-30b-5p
20systemic sclerosis; breast, lung and other cancers[26,28]M1 (UBE2F,SOCS3, UBE2J1) M2 (GNAI2)
hsa-miR-30c-5p
20breast, lung and other cancers[26]M1 (UBE2F,SOCS3, UBE2J1) M2 (GNAI2)
hsa-miR-9-5p
20squamous cell carcinoma[29]M2 (CXCL11) M5 (GCH1)
hsa-miR-30a-5p
19breast and other cancers[26]M1 (UBE2F,SOCS3, UBE2J1) M2 (GNAI2)
hsa-miR-30d-5p
19breast and other cancers[26]M1 (UBE2F,SOCS3, UBE2J1) M2 (GNAI2)
hsa-miR-613
19breast cancer[30]M2 (CXCL11) M5 (GCH1)
hsa-miR-302c-3p
17breast cancer[31]M1 (SOCS3, IRF9) M5 (GUCY1A3)
hsa-miR-302e
13lung cancer[32]M1 (IRF9) M5 (GUCY1A3)
hsa-miR-372-3p
12squamous cell carcinoma[33]M1 (IRF9) M5 (GUCY1A3)
hsa-miR-302a-3p
11breast cancer[31]M1 (IRF9) M5 (GUCY1A3)
hsa-miR-302b-3p
11breast cancer[31]M1 (IRF9) M5 (GUCY1A3)
hsa-miR-302d-3p
11breast cancer[31]M1 (IRF9) M5 (GUCY1A3)
hsa-miR-31-5p
11systemic sclerosis and breast cancer[34,35]M3 (KDELR2) M5 (PAX5, SPARC, GCH1)
hsa-miR-520a-3p
11breast cancer[36]M1 (IRF9) M5 (GUCY1A3)
hsa-miR-520b
11breast, ovarian and other cancers[37,38]M1 (IRF9) M5 (GUCY1A3)
hsa-miR-520c-3p
11breast cancer[39]M1 (IRF9) M5 (GUCY1A3)
hsa-miR-520d-3p
11breast cancer[40]M1 (IRF9) M5 (GUCY1A3)
hsa-miR-520e
11breast cancer[41]M1 (IRF9) M5 (GUCY1A3)
hsa-miR-181d-5p
10leukemia, colon cancer, glioblastoma[42,43,44]M1 (CBLB) M5 (PAX5, BCL2) M4 (AP1S3)
hsa-miR-181a-5p
8leukemia, breast cancer, neuroblastoma[42,45,46]M1 (CBLB) M5 (BCL2) M4 (AP1S3)
hsa-miR-181b-5p
8leukemia, lung cancer, neuroblastoma[42,46,47]M1 (CBLB) M5 (BCL2) M4 (AP1S3)
hsa-miR-181c-5p
8leukemia, sarcoma[42,48]M1 (CBLB) M5 (BCL2) M4 (AP1S3)
hsa-miR-211-5p
7renal cell carcinoma, melanoma, carcinoma, breast cancer[49,50,51]M5 (SPARC, BCL2) M6 (PSME1)
hsa-miR-204-5p
7lung and breast cancer, leukemia, carcinoma[52,53]M5 (SPARC, BCL2) M6 (PSME1)

Share and Cite

MDPI and ACS Style

Dolcino, M.; Tinazzi, E.; Puccetti, A.; Lunardi, C. In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis. J. Clin. Med. 2019, 8, 320. https://doi.org/10.3390/jcm8030320

AMA Style

Dolcino M, Tinazzi E, Puccetti A, Lunardi C. In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis. Journal of Clinical Medicine. 2019; 8(3):320. https://doi.org/10.3390/jcm8030320

Chicago/Turabian Style

Dolcino, Marzia, Elisa Tinazzi, Antonio Puccetti, and Claudio Lunardi. 2019. "In Systemic Sclerosis, a Unique Long Non Coding RNA Regulates Genes and Pathways Involved in the Three Main Features of the Disease (Vasculopathy, Fibrosis and Autoimmunity) and in Carcinogenesis" Journal of Clinical Medicine 8, no. 3: 320. https://doi.org/10.3390/jcm8030320

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop